Related Experiment Video

Updated: Dec 25, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity

Laura Pellegrini1, Sara Sileno2, Marco D'Agostino2

  • 1Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.

Cancers
|March 21, 2020
PubMed

Insights

Cancer therapies can harm the heart, causing cardiotoxicity. This review explores how microRNAs (miRNAs) are involved in cancer treatment-induced heart damage and could be therapeutic targets.

Area of Science:

  • Oncology
  • Cardiology
  • Molecular Biology

Background:

  • Cancer treatments, including chemotherapy, targeted therapy, and immunotherapy, offer significant progress but are limited by cardiotoxicity.
  • Cardiotoxicity manifests as ventricular dysfunction, cardiomyopathy, and heart failure, impacting patient outcomes.
  • Mechanisms like oxidative stress, DNA damage, and microRNA (miRNA) dysregulation contribute to cardiac toxicity.

Purpose of the Study:

  • To review cardiotoxicity induced by various cancer treatments.
  • To explore the role of microRNAs (miRNAs) in cancer treatment-related cardiotoxicity.
  • To identify potential miRNA-based therapeutic targets for mitigating cardiac damage.

Main Methods:

  • Literature review of studies on cancer treatment cardiotoxicity.
  • Analysis of mechanisms underlying cardiotoxicity, including oxidative stress and DNA damage.
  • Investigation of microRNA (miRNA) involvement in cardiac remodeling and toxicity.

Main Results:

  • Diverse cancer therapies induce cardiotoxicity with varying severity.
  • MicroRNAs (miRNAs) are crucial regulators of cardiac cell function and are dysregulated in cardiotoxicity.
  • Specific miRNAs show potential as biomarkers and therapeutic targets for cardiotoxicity.

Conclusions:

  • Cardiotoxicity remains a significant challenge in cancer care.
  • MicroRNA (miRNA) dysregulation is implicated in cancer treatment-induced heart disease.
  • Targeting miRNAs may offer novel strategies to prevent or treat cardiotoxicity.
Keywords:
cancer therapycardiotoxicitycardiovascular diseasesmicroRNAs

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

256

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K